CKD-519

DRUG3 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Dyslipidemia

Phase 1

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

CompletedNCT02156544

Chong Kun Dang PharmaceuticalDyslipidemia

Start: 2014-06-30End: 2015-08-31Updated: 2015-09-11

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

CompletedNCT02753504

Chong Kun Dang PharmaceuticalDyslipidemia

Start: 2016-04-30End: 2016-07-31Updated: 2017-07-13

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

CompletedNCT03210649

Chong Kun Dang PharmaceuticalDyslipidemia

Start: 2017-03-07End: 2017-04-24Updated: 2017-07-07